RPMI 8226 Cells

RPMI 8226 cells are a human myeloma cell line that was established in 1966 from the peripheral blood of a 61-year-old male patient with multiple myeloma. This cell line was named after the Roswell Park Memorial Institute (RPMI) where it was developed, and the number 8226 denotes its specific catalog number in the cell bank. The RPMI 8226 cell line is an important model system for studying multiple myeloma and related aspects of plasma cell biology, immunology research, and cancer therapy. RPMI 8226 cells are known to produce and secrete kappa light chains of immunoglobulins, a feature that is often exploited in research studies to investigate antibody production and secretion mechanisms. RPMI 8226 cells exhibit numerous chromosomal abnormalities, which are typical of multiple myeloma cells. These include translocations, deletions, and amplifications that affect various oncogenes and tumor suppressor genes. The human myeloma cell line RPMI 8226 are widely used in drug discovery and development research, and have been used to investigate drug resistance pathways and evaluating combination therapies. In summary, RPMI 8226 cells provide a critical in vitro model for multiple myeloma research, enabling the investigation of the biological and molecular mechanisms underlying this disease and the development of therapeutic strategies. Myeloma cell lines, Peripheral blood, Multiple Myeloma, Growth Conditions: Adherent/suspension, Biosafety level: BSL 1